In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146
The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the...
Gespeichert in:
| Veröffentlicht in: | Microbes and infection 2015-11, Vol.17 (11-12), p.738-744 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 744 |
|---|---|
| container_issue | 11-12 |
| container_start_page | 738 |
| container_title | Microbes and infection |
| container_volume | 17 |
| creator | Ong, Vanissa A. Lawrence, Amba Timms, Peter Vodstrcil, Lenka A. Tabrizi, Sepehr N. Beagley, Kenneth W. Allan, John A. Hocking, Jane S. Huston, Wilhelmina M. |
| description | The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound. |
| doi_str_mv | 10.1016/j.micinf.2015.09.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1738481101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1286457915001860</els_id><sourcerecordid>1738481101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-b8818678cd258a1d7e58f33c0a7ac254616d6d4b96e605c83bacb33868d920f83</originalsourceid><addsrcrecordid>eNp9kE1q5DAQRkXIkP8bhKBlNvZItizJm0BoMpMMgd7MQHZClmRcjW11JHWgb5OzzMmipjtZZlW1eFUf30PompKSEsp_rsoJDMx9WRHalKQtCWFH6IwK3haCspfjvFeSF6wR7Sk6j3FFMig4O0GnFa95Kyg9Q8PT_P_9DVLwOG6icesEHYyQttj3ODjj5oQXw6inrQWNU9Bm8JNOELEZYQajRwzRjzq5iJPHaXB4kR5TuMcwD_lV8gH_WVLGL9GPXo_RXR3mBfr36-Hv4rF4Xv5-Wtw_F4YRmYpOSiq5kMZWjdTUCtfIvq4N0UKbqmGccsst61ruOGmMrDtturqWXNq2Ir2sL9Dt_u86-NeNi0lNkHuNo56d30RFRS2ZpFlhRtkeNcHHGFyv1gEmHbaKErVzrFZq71jtHCvSquw4n90cEjbd5OzX0afUDNztAZd7voELKhpws3EWstGkrIfvEz4AX2qQVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1738481101</pqid></control><display><type>article</type><title>In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ong, Vanissa A. ; Lawrence, Amba ; Timms, Peter ; Vodstrcil, Lenka A. ; Tabrizi, Sepehr N. ; Beagley, Kenneth W. ; Allan, John A. ; Hocking, Jane S. ; Huston, Wilhelmina M.</creator><creatorcontrib>Ong, Vanissa A. ; Lawrence, Amba ; Timms, Peter ; Vodstrcil, Lenka A. ; Tabrizi, Sepehr N. ; Beagley, Kenneth W. ; Allan, John A. ; Hocking, Jane S. ; Huston, Wilhelmina M.</creatorcontrib><description>The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.</description><identifier>ISSN: 1286-4579</identifier><identifier>EISSN: 1769-714X</identifier><identifier>DOI: 10.1016/j.micinf.2015.09.004</identifier><identifier>PMID: 26369711</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Cell Line ; Chlamydia ; Chlamydia trachomatis - drug effects ; Chlamydia trachomatis - isolation & purification ; Clinical isolate ; Dipeptides - pharmacology ; Female ; HtrA ; Humans ; Inhibitor ; Organophosphonates - pharmacology ; Serine Endopeptidases - drug effects ; Serine Proteinase Inhibitors - pharmacology</subject><ispartof>Microbes and infection, 2015-11, Vol.17 (11-12), p.738-744</ispartof><rights>2015 Institut Pasteur</rights><rights>Copyright © 2015 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-b8818678cd258a1d7e58f33c0a7ac254616d6d4b96e605c83bacb33868d920f83</citedby><cites>FETCH-LOGICAL-c408t-b8818678cd258a1d7e58f33c0a7ac254616d6d4b96e605c83bacb33868d920f83</cites><orcidid>0000-0002-0879-1287</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.micinf.2015.09.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26369711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ong, Vanissa A.</creatorcontrib><creatorcontrib>Lawrence, Amba</creatorcontrib><creatorcontrib>Timms, Peter</creatorcontrib><creatorcontrib>Vodstrcil, Lenka A.</creatorcontrib><creatorcontrib>Tabrizi, Sepehr N.</creatorcontrib><creatorcontrib>Beagley, Kenneth W.</creatorcontrib><creatorcontrib>Allan, John A.</creatorcontrib><creatorcontrib>Hocking, Jane S.</creatorcontrib><creatorcontrib>Huston, Wilhelmina M.</creatorcontrib><title>In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146</title><title>Microbes and infection</title><addtitle>Microbes Infect</addtitle><description>The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.</description><subject>Cell Line</subject><subject>Chlamydia</subject><subject>Chlamydia trachomatis - drug effects</subject><subject>Chlamydia trachomatis - isolation & purification</subject><subject>Clinical isolate</subject><subject>Dipeptides - pharmacology</subject><subject>Female</subject><subject>HtrA</subject><subject>Humans</subject><subject>Inhibitor</subject><subject>Organophosphonates - pharmacology</subject><subject>Serine Endopeptidases - drug effects</subject><subject>Serine Proteinase Inhibitors - pharmacology</subject><issn>1286-4579</issn><issn>1769-714X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1q5DAQRkXIkP8bhKBlNvZItizJm0BoMpMMgd7MQHZClmRcjW11JHWgb5OzzMmipjtZZlW1eFUf30PompKSEsp_rsoJDMx9WRHalKQtCWFH6IwK3haCspfjvFeSF6wR7Sk6j3FFMig4O0GnFa95Kyg9Q8PT_P_9DVLwOG6icesEHYyQttj3ODjj5oQXw6inrQWNU9Bm8JNOELEZYQajRwzRjzq5iJPHaXB4kR5TuMcwD_lV8gH_WVLGL9GPXo_RXR3mBfr36-Hv4rF4Xv5-Wtw_F4YRmYpOSiq5kMZWjdTUCtfIvq4N0UKbqmGccsst61ruOGmMrDtturqWXNq2Ir2sL9Dt_u86-NeNi0lNkHuNo56d30RFRS2ZpFlhRtkeNcHHGFyv1gEmHbaKErVzrFZq71jtHCvSquw4n90cEjbd5OzX0afUDNztAZd7voELKhpws3EWstGkrIfvEz4AX2qQVw</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Ong, Vanissa A.</creator><creator>Lawrence, Amba</creator><creator>Timms, Peter</creator><creator>Vodstrcil, Lenka A.</creator><creator>Tabrizi, Sepehr N.</creator><creator>Beagley, Kenneth W.</creator><creator>Allan, John A.</creator><creator>Hocking, Jane S.</creator><creator>Huston, Wilhelmina M.</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0879-1287</orcidid></search><sort><creationdate>201511</creationdate><title>In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146</title><author>Ong, Vanissa A. ; Lawrence, Amba ; Timms, Peter ; Vodstrcil, Lenka A. ; Tabrizi, Sepehr N. ; Beagley, Kenneth W. ; Allan, John A. ; Hocking, Jane S. ; Huston, Wilhelmina M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-b8818678cd258a1d7e58f33c0a7ac254616d6d4b96e605c83bacb33868d920f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Cell Line</topic><topic>Chlamydia</topic><topic>Chlamydia trachomatis - drug effects</topic><topic>Chlamydia trachomatis - isolation & purification</topic><topic>Clinical isolate</topic><topic>Dipeptides - pharmacology</topic><topic>Female</topic><topic>HtrA</topic><topic>Humans</topic><topic>Inhibitor</topic><topic>Organophosphonates - pharmacology</topic><topic>Serine Endopeptidases - drug effects</topic><topic>Serine Proteinase Inhibitors - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ong, Vanissa A.</creatorcontrib><creatorcontrib>Lawrence, Amba</creatorcontrib><creatorcontrib>Timms, Peter</creatorcontrib><creatorcontrib>Vodstrcil, Lenka A.</creatorcontrib><creatorcontrib>Tabrizi, Sepehr N.</creatorcontrib><creatorcontrib>Beagley, Kenneth W.</creatorcontrib><creatorcontrib>Allan, John A.</creatorcontrib><creatorcontrib>Hocking, Jane S.</creatorcontrib><creatorcontrib>Huston, Wilhelmina M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Microbes and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ong, Vanissa A.</au><au>Lawrence, Amba</au><au>Timms, Peter</au><au>Vodstrcil, Lenka A.</au><au>Tabrizi, Sepehr N.</au><au>Beagley, Kenneth W.</au><au>Allan, John A.</au><au>Hocking, Jane S.</au><au>Huston, Wilhelmina M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146</atitle><jtitle>Microbes and infection</jtitle><addtitle>Microbes Infect</addtitle><date>2015-11</date><risdate>2015</risdate><volume>17</volume><issue>11-12</issue><spage>738</spage><epage>744</epage><pages>738-744</pages><issn>1286-4579</issn><eissn>1769-714X</eissn><abstract>The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>26369711</pmid><doi>10.1016/j.micinf.2015.09.004</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0879-1287</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1286-4579 |
| ispartof | Microbes and infection, 2015-11, Vol.17 (11-12), p.738-744 |
| issn | 1286-4579 1769-714X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1738481101 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Cell Line Chlamydia Chlamydia trachomatis - drug effects Chlamydia trachomatis - isolation & purification Clinical isolate Dipeptides - pharmacology Female HtrA Humans Inhibitor Organophosphonates - pharmacology Serine Endopeptidases - drug effects Serine Proteinase Inhibitors - pharmacology |
| title | In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T03%3A58%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%C2%A0vitro%20susceptibility%20of%20recent%20Chlamydia%20trachomatis%20clinical%20isolates%20to%20the%20CtHtrA%20inhibitor%20JO146&rft.jtitle=Microbes%20and%20infection&rft.au=Ong,%20Vanissa%20A.&rft.date=2015-11&rft.volume=17&rft.issue=11-12&rft.spage=738&rft.epage=744&rft.pages=738-744&rft.issn=1286-4579&rft.eissn=1769-714X&rft_id=info:doi/10.1016/j.micinf.2015.09.004&rft_dat=%3Cproquest_cross%3E1738481101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1738481101&rft_id=info:pmid/26369711&rft_els_id=S1286457915001860&rfr_iscdi=true |